Your Marketing & BD Infrastructure
What you're looking at is your complete marketing and business development infrastructure — not a content calendar, not a brand guidelines document, but a structured, usable foundation that defines who you serve, how you're positioned, how you communicate, and how you compete. This is the strategic layer that makes every downstream activity — content, proposals, new hire onboarding, agency briefings, website copy — consistent and intentional.
This was built from everything you shared in your intake, cross-referenced with your published website and materials. The intake was the starting point, not the endpoint. Where we found gaps, we flagged them. Where sources agreed, we built from them with confidence. Where they pointed in different directions, we explain how we resolved it.
Your job is to confirm that what we found is accurate. Use the notes fields to tell us where something doesn't match how you see your business. That confirmation activates the infrastructure and makes it yours.
Here is how your Backbone Framework is structured — what went in, what frameworks were applied, what you receive, and what you can do with it.
The six context files are yours. Any tool, any team member, any agency you ever work with can use them as the source of truth for how your business communicates and competes.
We reviewed your complete Backbone intake responses, your website (goodbonesmarketing.com — homepage, services, about, process, and client testimonial), and your marketing flyer (GBM-Flyer3.pdf). No content examples or past posts were submitted, so voice analysis was derived from intake responses and published materials. We note where this limitation matters.
Identifying buyers most likely to convert, retain, and refer — from firmographic and psychographic data, not assumptions.
The Big Five personality model applied to calibrate how content and messaging should be written for each buyer segment's psychology.
Tracing how each buyer type moves from problem awareness to purchase decision — identifying what they need to see at each stage.
Defining the emotional role your brand plays in your audience's lives — guiding voice, tone, and register across all communications.
Identifying not just competitors, but what buyers try before finding you — and why those approaches fall short.
Structured evaluation of sentence patterns, diction, tone, and structural habits across all available published materials.
The gap between your actual credentials and their current visibility. Credential-rich, community-embedded, structurally differentiated — but not yet consistently findable by the buyers who need you most.
Twenty years of community membership plus AI infrastructure that stays with the client. That combination is genuinely difficult for any agency or generic tool to replicate.
Activate this infrastructure and make you findable to buyers already experiencing the problems you solve. The strategic foundation is clear. Visibility is what needs to close.
Your business has a positioning problem that is the opposite of the one most marketing consultants describe. You are not underqualified for your market. You are one of the most credibly positioned people in the life sciences AEC and supplier community. Twenty years inside the industry, CPSM certification, ISPE chapter president, SMPS award winner, fifteen-plus Facility of the Year entries for major accounts. The credentials are not the gap. The gap is visibility — specifically, the gap between how well-positioned you actually are and how visible that positioning is to the buyers who would most benefit from your work.
Your infrastructure is now documented. What you do with it is up to you.
Two separate analyses: the first maps your position against the market at large; the second names your specific competitors and shows exactly where each one is a threat and where each one is an opening.
Built from your intake responses, your published materials, and external market research conducted across the AEC, life sciences construction, and B2B marketing automation sectors. Strengths and Weaknesses are internal — things your business controls, independent of any competitor. Opportunities reflect market conditions and buyer gaps that exist regardless of who else is in the market. Threats are structural forces — industry dynamics, buyer behavior patterns, and macro risks — that apply whether a named competitor exists or not.
- CPSM + ISPE Delaware Valley Chapter President + SMPS award winner — community credibility that cannot be manufactured without two decades inside the industry
- "Systems That Stay" delivery model builds permanent client-owned assets, not retainer dependency — structurally different from every alternative a buyer would evaluate
- Deep GMP / CQV / EPCM regulatory literacy means content passes the technical review that generic agency output consistently fails
- Former Director of Marketing at a billion-dollar Berkshire Hathaway firm — C-suite fluency when selling to enterprise and senior leadership
- ERA Science testimonial approved for public use — one validated proof point in a market where most proof is contractually silenced
- Blueprint to Batch podcast — direct editorial access to target buyer titles in a non-sales context that organic content cannot replicate
- Solo operator: capacity, delivery, and BD all depend on one person — the ceiling is the founder's available hours, full stop
- NDA constraints prevent naming pharma and biotech facility clients — social proof is limited in the market where peer validation carries the most weight
- No published case studies with hard ROI data — risk-averse enterprise buyers want quantified outcomes before committing
- Early revenue stage ($80K) limits budget for conference visibility, paid acquisition, and contractor support
- Pricing not publicly disclosed — creates self-qualification friction for buyers who research extensively before reaching out
- Website voice runs more formal than the brand's actual register — misaligns the first impression with the live engagement experience
- FDA and EMA AI guidance expanding rapidly — creating an urgent compliance question that the vast majority of marketing vendors cannot answer credibly
- Life sciences construction at decade highs driven by biopharma capacity buildout — AEC and EPCM firms are growing fast and their marketing infrastructure is not keeping up
- Senior engineer retirement wave at client firms creating an institutional knowledge crisis — the AI Knowledge Base product directly addresses a problem buyers are actively feeling
- Existing ISPE + SMPS community position enables warm introductions at near-zero acquisition cost — trust channels that take years to build are already in place
- Podcast guest relationships represent an untapped BD pipeline — conversations that haven't been converted to client exploration
- B2B buyers in regulated industries are increasingly skeptical of generic AI outputs — creating demand for domain-validated, compliance-aware automation that the market has not filled
- Large EPCM and AEC firms with dedicated IT budgets beginning to build internal AI and marketing automation teams — reducing the window where an external specialist is the default choice
- IT and legal departments structurally blocking AI vendor access — deals stall after champion engagement, not because of fit; the champion cannot close without clearing internal gatekeepers
- Generalist AI platforms (ChatGPT Enterprise, Microsoft Copilot) providing "good enough" automation for buyers who have not experienced what a validated, domain-specific system delivers
- Long B2B sales cycles in regulated industries — the gap between first engagement and closed deal creates revenue timing risk for a solo operator
Built from competitive intelligence gathered during the framework research phase, cross-referenced with named competitors in your intake. For each competitor, we identified what they do well (Threats that require a counter-strategy) and where they fall short (Opportunities to exploit in positioning and content). This analysis is specific to the three competitors you named: Forma Life Science Marketing, Altitude Marketing, and Gorilla 76.
- vs. Forma CPSM credential + active ISPE Chapter President — association standing Forma cannot replicate; buyers in this community know the difference
- vs. Forma "Systems That Stay" model delivers client-owned AI infrastructure — Forma delivers content on retainer with nothing permanent left behind
- vs. Altitude Deep EPCM and GMP-specific regulatory literacy — Altitude's life sciences work addresses commercial biotech brands, not proposal marketing and facility delivery
- vs. Altitude AI Automation Systems as a discrete, defined service line — Altitude has no equivalent offering in regulated AEC
- vs. Gorilla 76 ISPE + SMPS community access and regulatory credibility — Gorilla 76 has strong industrial B2B presence but zero penetration into life sciences construction
- vs. Gorilla 76 Domain-validated AI systems for GMP environments — Gorilla 76 cannot serve a client whose IT requires compliance-documented AI inputs
- vs. Forma Scale — Forma has a full agency team; Sandra is a solo operator with a hard capacity ceiling that Forma does not have
- vs. Forma Established pharma and biotech client relationships with multi-year tenure — displacing a trusted vendor requires a compelling event, not just a better offer
- vs. Altitude National brand recognition in life sciences marketing — Altitude has built visible market presence over more years and with more team resources
- vs. Altitude Full-service breadth — Altitude covers strategy, brand, digital, and execution under one contract; GBM is specialists-only
- vs. Gorilla 76 Published content marketing volume and podcast scale — Gorilla 76 has built a recognizable industrial B2B content brand with more production output than GBM currently generates
- vs. Forma No AI automation capability — Forma operates entirely on a traditional retainer model; buyers who want client-owned systems get nothing from them
- vs. Forma No "Systems That Stay" positioning — any buyer who has experienced retainer dependency is a conversion candidate when they see the alternative framed clearly
- vs. Altitude Not EPCM or proposal-marketing specific — their life sciences practice doesn't address the shortlist and RFP layer where Sandra's domain expertise lives
- vs. Altitude No ISPE or SMPS community standing — buyers who rely on association relationships for vendor validation have no warm path to Altitude
- vs. Gorilla 76 Has not penetrated life sciences AEC — their industrial positioning stops at general manufacturing; no GMP, no ISPE, no regulated facility context
- vs. Gorilla 76 Cannot serve clients requiring compliance-documented AI — any buyer whose IT department requires validated AI inputs is outside Gorilla 76's current capability
- Forma Deep pharma and biotech client roster with multi-year relationships — the buyer who has already worked with Forma has loyalty and switching cost working against you
- Forma Adding AI capabilities — if Forma develops an AI service line, the differentiation gap on automation narrows and the established relationship advantage compounds
- Altitude Full-service appeal for enterprise buyers who want a single vendor — the "one agency for everything" pitch is a strong alternative for a buyer who hasn't yet identified AI infrastructure as a distinct need
- Altitude National brand recognition creates shortlist presence by default — Sandra has to earn that shortlist position in each new opportunity
- Gorilla 76 Proven content marketing playbook for industrial B2B — a buyer in adjacent industrial markets who finds Gorilla 76 first may not realize life sciences AEC marketing requires a different specialist
- Gorilla 76 Expanding into adjacent regulated verticals — if they move toward pharma AEC with intentionality, the white space narrows
| Competitor | Their Biggest Threat to You | Your Biggest Opening vs. Them | How to Win the Comparison |
|---|---|---|---|
| Forma Life Science Marketing | Established multi-year client relationships in pharma and biotech AEC — high switching cost once embedded | No AI automation capability; no "Systems That Stay" model — buyers who want owned infrastructure get nothing from Forma | Lead with the structural difference: Forma builds content on your behalf; GBM builds infrastructure that belongs to you after the engagement ends |
| Altitude Marketing | Full-service breadth and national life sciences brand recognition — attractive single-vendor option for buyers who haven't isolated AI infrastructure as a need | Not EPCM or GMP-specific; no ISPE community standing — the proposal marketing and facility delivery layer is a gap they do not fill | Lead with the EPCM layer: CPSM + GMP/CQV regulatory literacy is a credential stack Altitude cannot replicate without industry years inside AEC |
| Gorilla 76 | Proven industrial B2B content brand with high production volume — buyers in adjacent markets may find them first | Zero life sciences AEC penetration; no ISPE presence; cannot serve compliance-document-requiring AI buyers | Own the ISPE + SMPS community channel explicitly and publicly — your association standing is the one advantage Gorilla 76 cannot manufacture or accelerate |
Your Audience
Five buyer profiles — one for every audience segment you listed in your intake — built from ICP methodology and psychographic analysis, including how each segment moves through their buying journey and which services apply to each.
Post-pandemic reshoring of pharmaceutical manufacturing and cell/gene therapy scale-up is accelerating EPCM and cleanroom construction pipelines through 2028. Firms that cannot demonstrate validated facility delivery credentials face early disqualification from clinical-to-commercial mandates, raising the credibility floor for every marketing touchpoint in this segment.
AEC and Facility Delivery Firms
Who They Are
Architecture, engineering, construction management, and specialty contracting firms that design, build, and commission life sciences facilities — EPCM firms, MEP engineers, cleanroom contractors, CQV specialists. The buyer is the VP of Marketing or Director of BD — often the only dedicated marketing person in the firm, responsible for everything from capability statements to ISPE award submissions.
What Makes Them Ready to Engage
- Lost a proposal shortlist to a competitor with weaker credentials but stronger marketing materials
- New VP of BD or Director of Marketing joined in the last 90 days and inherited a program they didn't build
- An ISPE Facility of the Year award cycle is approaching and the firm wants to submit or improve
- The marketing person just left and leadership is deciding whether to hire again or restructure
- The firm won a marquee project and no content plan exists to build visibility around it
- A peer firm they respect just launched content that their own program doesn't match
What They Need to Believe
That you are genuinely inside their community, not learning it on their engagement. And that what you build will sound like them — not like a marketing agency's version of them.
Where to Reach Them
Psychographic Profile (OCEAN)
Who They Are
The VP of Marketing at an EPCM or life sciences AEC firm owns everything from capability statements to award submissions. They are usually the most senior dedicated marketing person in the building — and often the only one. They are accountable for how the firm looks on paper, on LinkedIn, and in front of a client selection committee. When a proposal shortlist is missed, they feel it personally. When the firm wins a marquee project and generates no content around it, they know exactly why.
What Triggers Them to Act
- Firm lost a shortlist to a competitor with weaker technical credentials but stronger marketing materials
- CEO or Managing Director asked why the firm isn't more visible at ISPE events
- New strategic plan includes market expansion and the marketing capability doesn't exist to support it
- An ISPE Facility of the Year cycle is approaching and the last submission was rejected or weak
- Senior marketing team member resigned and leadership is deciding whether to rebuild or restructure
What They Need to Believe
That you already understand their market before the first call — and that the systems you build will still be running and improving long after the engagement ends.
Their Personal Stakes
Their job security is tied to proposal win rates and market visibility. A failed agency engagement doesn't just waste budget — it costs them credibility with the BD Director and the CEO. They need a vendor who can walk into a room of engineers and speak their language without being briefed.
How They Make Decisions
Methodical. High conscientiousness — they will research Sandra's LinkedIn, check her ISPE profile, read her posts for six weeks before reaching out. They want written materials, not a sales call. Peer validation matters: if someone in their SMPS network has worked with Sandra, that reference carries more weight than any case study.
What They've Already Tried
A general B2B marketing agency that didn't understand cleanrooms or proposal language. A freelance copywriter who required six rounds of technical editing. Internal staff stretched too thin. They've tried enough to know that domain depth is non-negotiable — what they haven't found is a vendor who combines it with AI infrastructure.
Who They Are
The Director of BD at an EPCM or AEC firm is measured on pipeline — specifically on proposal win rates, qualified opportunity volume, and new market penetration. They live in the RFP cycle. They know every competitor they lost to last quarter. They are the internal champion for anything that improves proposal quality, accelerates response time, or opens new market relationships. They own the relationship with clients and prospects — and they feel the cost of a weak marketing infrastructure directly, in the room, during selection presentations.
What Triggers Them to Act
- Proposal win rate dropped below target last quarter and leadership is asking why
- Firm expanding into a new geography or project type where their marketing presence is zero
- Manual RFP response process is consuming 60+ engineer hours per submission
- A key senior engineer retired and six months of institutional project knowledge left with them
- Competitor is showing up at ISPE events and on LinkedIn with visible market presence; their firm isn't
- New joint venture or teaming partnership requires professional marketing materials that don't exist
What They Need to Believe
That this isn't a content production engagement. That what gets built is a BD infrastructure — proposal intelligence, market monitoring, and a knowledge base that makes the next RFP take half the time.
Their Personal Stakes
Win rates. Revenue pipeline. If they champion an AI or marketing vendor and it produces generic output that embarrasses the firm in front of a client selection committee, it lands on them. They need something that works in the room with a VP of Engineering — not something that looks good in a demo.
How They Make Decisions
More decisive than the VP of Marketing but still relationship-driven. Will ask a peer at ISPE or SMPS if they've worked with Sandra. Wants to understand the ROI in pipeline terms — "what does this do for our proposal win rate?" — before any conversation about process or methodology. Responds well to specificity: name the exact RFP pain, the exact proposal bottleneck, the exact competitive intelligence gap.
What They've Already Tried
They've tried asking the marketing person to solve a sales problem. They've had engineers write their own proposal content (slow, painful, generic). They may have tried a proposal management tool or a CRM that didn't integrate with how the BD team actually works. They know what the gap is — they've been living with it for years.
- Cleanroom design and build
- MEP engineering for controlled environments
- Commissioning, qualification, and validation (CQV) when embedded in AEC
- EPCM and EPCMV project delivery firms
- Specialty trades: flooring, HVAC, process piping, electrical for GMP
- Facility lifecycle consulting
- General commercial construction with no life sciences practice
- Residential AEC
- Infrastructure or civil engineering without pharma application
- Government or municipal construction
- Active marketing or BD investment is evident
- Company size 25 to 500 employees
- Posting on LinkedIn 2x or more per month
- Exhibits or speaks at ISPE or Interphex
- Current job opening for marketing or BD
- Recently won a major project or award
- Budget: $20K or more confirmed or strongly implied
- Some marketing activity, not consistent
- Company size 10 to 25 or 500 to 2,000
- LinkedIn presence but low frequency
- Attends but does not sponsor events
- No current marketing role posting
- Budget signals are indirect or unclear
- No visible marketing investment
- Under 10 or over 2,000 employees
- Minimal or no LinkedIn presence
- No event presence or industry engagement
- End user or pharma company (disqualify)
- On DO NOT CONTACT list (disqualify)
- Company page posts fewer than 2x per month or hasn't posted in 30 or more days
- CEO or principal posting personal content with no amplification from the company page
- Project completions or awards mentioned in comments but never formally posted
- Job postings for: Marketing Coordinator, Proposal Writer, Content Creator, BD Specialist
- Low engagement (under 10 likes) despite 500 or more followers
- Company page profile is incomplete: no tagline, no about section, no featured content
- Website was last updated more than 2 years ago: stale project pages and team bios
- No blog, insights section, or thought leadership content on the site
- Firm submits to awards programs (ISPE Facility of the Year, Zweig) but does not publicize wins
- News mentions in trade publications (ENR, Pharmaceutical Technology) with no company follow-up
- Job board activity: postings for marketing, BD, or communications roles
- Win more contracts in GMP and regulated facility sectors
- Build brand recognition in a market where reputation drives new business
- Differentiate from commodity construction firms by demonstrating technical depth
- Get more marketing output without adding internal headcount
- Become the go-to name in their region or specialty niche
- Marketing is reactive, not strategic: they post when someone remembers to
- Their best projects are invisible because no one is documenting them in real time
- BD and operations are the priority; marketing gets the leftover budget
- Cannot produce consistent LinkedIn, proposals, and award submissions without burning out their one marketing person
- Know AI could help but do not know where to start without creating compliance risk
- Technical accuracy: will not publish content that misrepresents GMP requirements
- Long-term relationships over transactional vendor engagements
- ROI and efficiency: they want systems and outcomes, not hourly billing
- A marketing partner who already knows what an EPCMV is
- Ownership of their tools and systems: not dependence on a vendor they cannot exit
- Publishing content that makes them look uninformed in front of pharmaceutical clients
- Investing in marketing and getting nothing measurable in return
- Losing control of their brand voice to an outsider
- Competitors out-marketing them while they are heads-down on project delivery
- AI won't work because it can't be customized for their specific work
| What They're Currently Using | Typical Weakness or Gap | Your Displacement Angle |
|---|---|---|
| No formal marketing vendor Doing it all internally with a coordinator |
Inconsistent output, low quality, strategically unfocused, coordinator is overwhelmed | You are not replacing a person. You are building the infrastructure the coordinator never had. |
| General marketing agency No AEC or life sciences experience |
Agency doesn't understand GMP, cannot write technically, produces generic content that embarrasses the firm | Industry credibility and regulated environment expertise: you speak their language before the first meeting. |
| PR firm Handling press releases and award submissions only |
No social media strategy, no content plan, no LinkedIn, no lead-generation angle | Full marketing and BD infrastructure: from weekly LinkedIn posts to campaign-level thought leadership. |
| SMPS-member marketing consultants AEC-focused but rarely life sciences-specialized |
AEC-focused but rarely have life sciences specialization or AI capabilities | GMP depth plus AI automation: a combination SMPS generalists cannot match. |
"I have spent nearly 20 years in biopharma marketing, and most of that time I was on the other side of the table, working with AEC and facility delivery partners just like yours. I know what it takes to market in a world where your clients are FDA-regulated, your timelines are compressed, and one wrong word in a proposal can cost you a contract."
"Here is what I see consistently with firms in your space: the work is excellent, the pipeline is real, but the marketing infrastructure has not kept pace with the growth. You are relying on one or two people to handle proposals, LinkedIn, awards, social media, and thought leadership, and something always slips. That is not a bandwidth problem. That is a systems problem."
"What Good Bones Marketing builds is marketing and BD infrastructure, powered by AI, that turns your existing work, projects, and expertise into a consistent stream of output. You get the strategy, the content, and the automation without hiring a full marketing team or dealing with an agency that has to look up what a cleanroom is."
"Hi [Name], I spent nearly 20 years in biopharma marketing working alongside firms like yours: AEC companies, EPCM groups, specialty contractors building GMP facilities. I know the work you do, and I know how hard it is to market it well when BD and project delivery come first. I help life sciences facility delivery firms build marketing infrastructure that runs consistently without adding headcount. Would a 20-minute call be worth it to see whether this is something that could move the needle for you this year?"
Great: that means you have a foundation. Most firms with one person find that the bottleneck isn't the person, it's the system. What I build sits behind your existing team and handles the volume they can't get to.
Referrals built your firm. But referrals alone won't take you into a new market or a new geography. That's where marketing infrastructure pays for itself: it keeps you visible to people who haven't met you yet.
You don't need to be ready for AI. You need to be ready for better marketing output. The AI is the engine under the hood: what you see is consistent LinkedIn content, better proposals, and a brand presence that reflects the quality of your work.
| Channel | Key Events and Venues | Approach | Cadence |
|---|---|---|---|
| ISPE Events | ISPE Annual Meeting, ISPE Delaware Valley Chapter, ISPE Pharma 4.0 | Attend, speak when possible. Use Sandra's chapter president role as credibility anchor. Direct conversation before email follow-up. | 3 to 4x per year national; monthly for chapter events |
| Email Outreach | Direct to CEO, VP BD, or VP Marketing | Industry credibility hook first. Reference a specific project, award, or LinkedIn post. Under 150 words. | Initial email plus 2 follow-ups over 3 weeks. Quarterly nurture. |
| Company pages, BD and marketing leader profiles | Research signals before connecting. Comment on their content 2 to 3 times before sending a connection request. DM after connection, not before. | Daily monitoring of target list; outreach when a trigger event is spotted | |
| Trade Publications | ENR, Pharmaceutical Technology, Cleanroom Technology | Watch for feature mentions of target firms. Use as research for a personalized email opener. | Weekly scan |
| Awards Cycles | ISPE Facility of the Year, ENR Top Specialty Contractors, ABC Excellence in Construction | Identify firms that win awards and don't publicize them: this is a direct pain point opener. | Annually Q1 to Q2 |
Pull the company on LinkedIn and their website. Answer each question. Total score determines tier assignment.
| # | Qualifying Question | Pts | Y? |
|---|---|---|---|
| 1 | Does the company specialize in life sciences, pharma, biotech, or GMP facility delivery, not general construction? | 2 | |
| 2 | Is company size between 10 and 2,000 employees? | 1 | |
| 3 | Is there an English-speaking contact in North America or Europe I can reach? | 1 | |
| 4 | Is there any visible marketing investment: active LinkedIn, recent website updates, event presence, or awards? | 2 | |
| 5 | Does the company have fewer than 3 internal marketers (or none listed on LinkedIn)? | 1 | |
| 6 | Is there a current or recent job posting for a marketing, BD, or proposal-writing role? | 1 | |
| 7 | Is the company NOT on the Do Not Contact list and NOT a pharma, CDMO, or biotech end-user? | 1 | |
| 8 | Has there been a trigger event in the last 90 days: new project win, award, leadership change, expansion, or event sponsorship? | 1 |
- Pharmaceutical manufacturers, CDMOs, biotech companies, cell and gene therapy companies, hospitals, or medical device manufacturers
- General commercial, residential, or infrastructure AEC firms with no life sciences practice
- Freelance architects, independent consultants, or sole proprietors under 10 employees
- Firms located exclusively outside North America and Europe with no Western market presence
- Companies where the only decision-maker is procurement or legal with no accessible marketing or BD contact
- Companies over 2,000 employees: budget exists but procurement cycles add significant delay
- Firms that are purely referral-driven with no outbound marketing appetite and no acknowledgment of a marketing gap
- Organizations recently acquired by a large parent company where brand and marketing decisions may be frozen during integration
The industry-wide shift from stainless steel to single-use bioprocessing infrastructure is compressing equipment replacement cycles and opening new supplier entry points at Tier 1 pharma accounts. Suppliers that cannot demonstrate regulatory compliance credibility in their marketing materials face early-stage disqualification from strategic account evaluations before formal procurement opens.
Systems, Equipment, and Materials Suppliers
Who They Are
Manufacturers and OEMs selling capital equipment, automation systems, single-use technologies, cleanroom components, and GMP-critical products to the life sciences facilities the first segment builds and operates. The buyer is typically the VP of Sales or CEO — running marketing as a side responsibility and now needing a system that matches the firm's growth ambitions.
What Makes Them Ready to Engage
- Major trade show approaching (CPhI, ISPE, Interphex) and digital presence doesn't match event presence
- New VP of Sales or BD Director joined with a mandate to modernize go-to-market
- A competitor just published visible, professional content that made the contrast uncomfortable
- Entered a new product category with no marketing foundation for the new offering
- A strategic account asked for a capability overview and the firm scrambled to produce materials
What They Need to Believe
That investing in marketing infrastructure will generate pipeline — tied to how strategic accounts find and evaluate suppliers before they ever reach out.
Where to Reach Them
Psychographic Profile (OCEAN)
Who They Are
The VP of Sales at a capital equipment OEM is measured on pipeline -- specifically on new account acquisition, strategic account penetration, and trade show ROI. They know every competitor who showed up at CPhI with a polished content presence; they felt that comparison firsthand. They are the internal champion for any go-to-market improvement that gives the sales team leverage without adding headcount. And they know the ceiling on relationship-driven selling: it is the size of their personal network.
What Triggers Them to Act
- Major trade show approaching with no supporting digital presence to extend the event investment
- Entered a new market segment or geography where pipeline is zero and the personal network doesn't reach
- Lost a strategic account evaluation to a competitor with weaker technical specs but stronger marketing credibility
- CEO asked why pipeline isn't growing at the rate the engineering quality should justify
- A strategic account asked for a capability overview document that didn't exist in any usable form
What They Need to Believe
That content infrastructure will generate inbound from strategic accounts before the next evaluation cycle begins -- and that the ROI is measurable in pipeline terms, not marketing metrics.
Their Personal Stakes
Win rates and strategic account penetration. If they champion a marketing investment that produces generic content embarrassing the firm in front of a Tier 1 procurement team, it lands on them directly. They need something that survives contact with a VP of Engineering or a procurement committee, not something that looks impressive in a demo.
How They Make Decisions
More direct than AEC buyers. Fewer committee layers. Responds to pipeline ROI framing over methodology. Wants to see proof fast -- the ERA Science case is the asset that opens the conversation. Will ask: "Has this worked for a company in our space?" before any discussion of process.
What They've Already Tried
A founder-managed brand that doesn't scale to their ambitions. A general B2B agency without life sciences regulated-environment knowledge that required constant re-education. Sporadic trade press releases that didn't build a pipeline. They know what's missing -- a system that gives the sales team marketing leverage before every strategic account conversation.
Who They Are
The CEO of a founder-built OEM built the company on technical excellence and personal relationships. Marketing has been their side project for a decade. They are proud of the product and the engineering team behind it. They are increasingly aware that the company's growth ceiling is tied to visibility with accounts that don't already know them -- and that the VP of Sales they just hired needs marketing support they don't have a system to provide.
What Triggers Them to Act
- Hired a new VP of Sales who is asking for marketing infrastructure the company doesn't have
- Entering a new geography or product category with no marketing foundation to support it
- A strategic account asked for a comprehensive capability overview that didn't exist in any form
- Trade show investment isn't converting to strategic account relationships at the rate the investment justifies
- A competitor they consider technically inferior published content that made them look like the authority first
What They Need to Believe
That a system built on their firm's actual language, technical specifications, and regulatory context will produce content their engineering team respects -- not content the team has to correct before they'll allow it out the door.
Their Personal Stakes
The brand IS their reputation. They will not associate with a marketing system that oversimplifies or misrepresents their product line. Their engineering team's credibility with Tier 1 accounts is what they protect above everything else. A single piece of inaccurate marketing content in front of a strategic account's procurement team is worse than no marketing at all.
How They Make Decisions
Direct budget authority -- can move faster than AEC buyers with fewer approval layers. But highly protective of brand accuracy. Will want to see output their engineering team won't correct before agreeing to anything. The conversation that matters isn't ROI -- it's "will this sound like us?" If the output quality passes, the decision is fast.
What They've Already Tried
Done it themselves with inconsistent discipline for years. Occasional trade press piece that didn't build pipeline. A junior team member managing LinkedIn with no strategy and no system behind it. They've built an excellent company -- they've just never built a marketing infrastructure to match it.
- Single-use technology: bags, tubing assemblies, bioreactor systems
- Process automation and control: SCADA, DCS, batch systems for GMP
- Cleanroom consumables and modular equipment
- Specialty lab equipment with GMP documentation packages
- Facility services: calibration, qualification, preventive maintenance
- Raw materials and excipients with regulatory dossiers
- General industrial suppliers with no pharma-grade certifications
- Consumer-facing product companies
- Office supply or general MRO distributors
- Commodity chemical suppliers with no regulated industry focus
- Holds FDA 510(k), ISO 13485, or USP certifications visibly advertised
- Company size 20 to 500 employees in life sciences vertical
- Exhibiting at Interphex, BIO, or ACHEMA
- Active LinkedIn page with product and application content
- Current job posting for marketing, demand gen, or field marketing
- Recent product launch or regulatory clearance announcement
- Life sciences product line but also sells to adjacent industries
- Company size 10 to 20 or 500 to 2,000
- Attends events but is not a regular exhibitor
- Low-frequency social media but website is current
- No open marketing role but has a small team
- No visible pharma or biotech application
- Under 10 or over 2,000 employees
- No event presence or marketing investment
- No English-speaking contact in North America or Europe
- Already working with a large marketing agency or PR firm
- Company posts product specs but no application content or case studies
- Sales team members posting independently but no coordination with company page
- New product or regulatory announcement with no follow-through content series
- Job posting for: Field Marketing Manager, Product Marketing Specialist, Content Strategist
- Low LinkedIn engagement relative to the size of their customer base
- Trade show announcements with no pre-show or post-show content
- Website has product data sheets but no application notes or customer success stories
- No blog, white paper, or technical content section
- Press releases issued but not amplified anywhere beyond the press release wire
- Conference appearances listed on the website with no recap content
- Distributor network is large but no-direct lead generation infrastructure is visible
- Grow direct sales to pharma and biotech without full reliance on distributors
- Be found earlier in the procurement and specification process
- Build technical credibility that accelerates vendor qualification
- Get marketing output that matches the quality of their product documentation
- Enter new therapeutic areas or geographic markets
- Marketing budget is product-promotion-focused, not education or awareness-focused
- Field sales team carries all brand reputation but cannot scale
- Content is technical but not engaging: data sheets but no stories
- They know their product is superior but prospects don't know they exist
- Marketing cannot write in the language of a pharma QA manager or process engineer
- Technical accuracy is non-negotiable: product claims must be supported
- Regulatory alignment: content must not create compliance risk for their customers
- Practical ROI: they need to see how content converts to qualified conversations
- A partner who understands the difference between a CDMO and a CMO
- Speed: they move fast around product launches and trade show cycles
- Publishing content that makes technical claims they can't support in a customer audit
- Marketing spend that doesn't reach pharma procurement or process engineering teams
- Losing ground to larger competitors with more marketing investment
- AI-generated content that doesn't match their product's precision image
- Being too slow to market when a competitor launches a similar product
| What They're Currently Using | Typical Weakness or Gap | Your Displacement Angle |
|---|---|---|
| Internal marketing team Product managers writing their own content |
PMs know the product but can't write for buyers; content is technical without being persuasive | You translate product expertise into buyer-ready content: application stories, comparison guides, and thought leadership that moves a procurement decision. |
| Trade show PR agency Managing press releases and exhibit logistics |
No digital strategy, no LinkedIn continuity, no between-show content | Full marketing infrastructure that extends trade show presence into a year-round content and demand generation program. |
| General B2B agency No life sciences or regulated industry experience |
Generic content that embarrasses the supplier in front of pharma QA and procurement teams | Industry fluency from day one: you don't need to explain what USP <1> is or why extractables and leachables matter. |
| Distributor-managed marketing Relying on distributor channels for brand exposure |
Brand is invisible; distributor controls the customer relationship and messaging | Build a direct-to-buyer brand presence that creates pull before a distributor is even in the conversation. |
"Your product is designed for pharma and biotech buyers. But most marketing content in this space is written for engineers, not procurement teams and QA managers who are deciding whether to put you on their approved vendor list. I've spent nearly 20 years in biopharma marketing, and I know both audiences and how to write for both of them in the same document."
"What I see with suppliers in your position: excellent products with thin content programs. Data sheets, a product page, maybe a white paper from 2019. Your competitors with lower-performing products are getting found first because they're showing up on LinkedIn, at conferences, and in application notes before you are. That's a marketing infrastructure problem, not a product problem."
"What Good Bones Marketing builds is marketing infrastructure powered by AI that turns your existing product expertise, application knowledge, and regulatory credentials into a consistent content and demand generation program. You get more output with less internal effort, and it all speaks the language of your pharma and biotech buyers."
"Hi [Name], I've spent nearly 20 years in biopharma marketing, and one pattern I see with suppliers like yours is excellent products with thin brand presence. Your buyers are specifying vendors before they even reach out to a sales rep: they're looking at LinkedIn, trade publications, and application notes. I help life sciences suppliers build marketing infrastructure that creates pull before the first sales conversation. Would it be worth 20 minutes to see if this is relevant to where you're trying to grow this year?"
Your distributors handle their marketing, which includes your products. That's not the same as having a brand presence for your company directly. What happens when a pharma buyer searches for you independently, before a distributor is in the picture?
That's exactly why this works: I don't need you to become a marketing company. I need your technical expertise. The system converts what your team already knows into content that reaches the people who buy from you.
That's the right concern and the reason GBM's process works differently. AI handles the structure, speed, and consistency; your team reviews everything before it goes out. The output matches your technical standards because you're the final check, not the AI.
| Channel | Key Events and Venues | Approach | Cadence |
|---|---|---|---|
| Industry Trade Shows | Interphex, BIO International, ACHEMA, DCAT Week, CPhI North America | Walk the show floor before the event. Note exhibitors without post-show content follow-through. Use as personalized email opener. | 4 to 6 major events annually; pre-show list review 4 weeks out |
| Marketing, product management, and commercial leadership profiles | Identify companies with active LinkedIn pages but inconsistent cadence. Comment before connecting. Reference a specific product or recent announcement. | Daily monitoring; outreach when show season or product launch signals appear | |
| Email Outreach | Direct to VP Marketing, VP Commercial, or CEO for smaller firms | Lead with the distributor-gap insight or the buyer-language insight. Under 150 words. Reference something specific about their product or category. | 3-touch sequence over 3 weeks; quarterly nurture for Tier 2 |
| ISPE and PDA Supplier Networks | ISPE Annual Meeting supplier exhibits, PDA Annual Meeting | Sandra's ISPE chapter president role opens supplier conversations. Warm intro is better than cold email for this segment. | 2 to 3 national events per year |
Pull the company on LinkedIn and their website. Answer each question. Total score determines tier assignment.
| # | Qualifying Question | Pts | Y? |
|---|---|---|---|
| 1 | Does the company supply to pharma, biotech, or GMP manufacturing customers as a primary market (not a side channel)? | 2 | |
| 2 | Is company size between 10 and 2,000 employees? | 1 | |
| 3 | Is there an accessible English-speaking marketing or commercial contact in North America or Europe? | 1 | |
| 4 | Is there any visible marketing investment: LinkedIn activity, event presence, white papers, or application notes? | 2 | |
| 5 | Does the company have fewer than 3 internal marketers or is relying on distributors for brand exposure? | 1 | |
| 6 | Has there been a recent product launch, regulatory clearance, or trade show appearance in the last 6 months? | 1 | |
| 7 | Is the company NOT an end-user pharma manufacturer and NOT on the Do Not Contact list? | 1 | |
| 8 | Is there a visible gap between product quality and marketing output (strong products, weak content program)? | 1 |
- Pharmaceutical manufacturers, CDMOs, biotech companies, or any regulated end-user of these products
- General industrial suppliers with no pharma-specific certifications or customer base
- Distributors acting as principals (they distribute but don't manufacture or develop products)
- Companies where the only accessible contact is procurement with no marketing or commercial lead reachable
- Firms located exclusively outside North America and Europe with no Western market presence
- Companies over 2,000 employees: typically have mature marketing teams, longer buying cycles for external agencies
- Suppliers already under contract with a major marketing agency (confirm before outreach)
- Companies whose life sciences business is less than 30% of revenue: competing priorities, budget tied to other verticals
FDA's Case for Quality initiative and the proliferation of remote inspection protocols are forcing life sciences firms to modernize quality systems infrastructure faster than internal teams can manage. CQV and eQMS specialists with visible, technically credible content pipelines are capturing demand that was previously invisible to their markets, while firms without a content strategy remain dependent on a referral network that saturates over time.
Digital, Quality, and Compliance Infrastructure Firms
Who They Are
CQV specialists, computerized system validation firms, data integrity providers, and LIMS/MES/eQMS vendors supporting regulated environments. Typically founded by a technical expert who built a consulting practice on deep domain expertise and has been growing through referrals. Their professional identity is precision and accuracy — in a market where errors have regulatory consequences.
What Makes Them Ready to Engage
- A competitor published a white paper on a regulatory topic the firm has more expertise in
- The founder is speaking at a conference and wants content that extends the impact
- New FDA or EMA guidance was published and the firm is well-positioned to respond — but hasn't
- Expanding from consulting into software or entering a new geography
- A major engagement concluded and the firm wants visibility around what was accomplished
How They Decide
The most conservative of the three segments. Content that oversimplifies their work will disqualify you faster than any objection. The most effective approach is technical, substantive, and regulation-aware. Regulatory commentary, specific arguments defended with the vocabulary of the field.
Where to Reach Them
Psychographic Profile (OCEAN)
Who They Are
The CEO or founder of a CQV consulting firm, CSV specialist, or eQMS vendor built the company on deep technical precision. They know their regulatory subject matter better than anyone in the room. Their professional identity is built on the accuracy and rigor of their work -- and their biggest fear is that marketing will make them look like everyone else in a space where differentiation is built entirely on demonstrated depth. They have watched less rigorous competitors claim authority on topics they have spent a decade mastering.
What Triggers Them to Act
- A competitor published a white paper on a regulatory topic the firm has more expertise in -- and it generated visibility they didn't
- FDA or EMA published new guidance they are well-positioned to interpret, but they have no distribution channel to respond
- The founder is speaking at a conference with no content strategy to extend the impact beyond the room
- A major client engagement concluded with outstanding results that nobody outside that client knows about
- Expanding into a new geography or regulatory framework with no marketing infrastructure to announce it
What They Need to Believe
That a marketing system can represent their technical depth accurately and consistently -- and that building it will not require continuous correction from their team to keep it from misrepresenting their expertise.
Their Personal Stakes
Their technical reputation is their entire competitive advantage. They will not associate with content that misuses regulatory language, oversimplifies validation protocols, or makes claims their team cannot stand behind. A single technically inaccurate piece of content in the wrong hands destroys credibility they have spent a decade building. The downside risk of getting marketing wrong is more visible to them than the upside of getting it right.
How They Make Decisions
Slow and deliberate. The most conservative buyer across all three core segments. Will read Sandra's published content carefully for technical accuracy before considering a conversation. A single imprecise claim ends the evaluation. May take months at the evaluation stage -- not because of budget or approval layers, but because the trust threshold is extremely high. Often starts with a narrow, well-defined project to test output quality before committing to a system.
What They've Already Tried
Nothing structured. A junior team member asked to post on LinkedIn with inconsistent results. A white paper written by the founder that went nowhere because no distribution system existed. They know exactly what the output should look like -- they write it themselves when they have time. What they haven't found is a system that can produce that output without them doing it manually every time.
Who They Are
The VP of Business Development at a CQV or eQMS firm is rare. Most companies in this segment grew entirely on the founder's reputation and referral network. When this role exists, it signals the firm has crossed a growth threshold and is deliberately building a pipeline engine beyond personal relationships. They are typically constructing a BD function from scratch in a culture where technical rigor has always been the primary competitive asset and marketing has never been a structured priority.
What Triggers Them to Act
- Carries a revenue target with no systematic path to hit it -- the referral network is saturated
- Trying to expand into a new geography or regulatory framework where the firm has no existing relationships
- Needs content to support the founder's speaking schedule and translate conference presence into pipeline beyond the room
- Wants to generate inbound inquiries that don't depend on the founder being present in every conversation
- A competitor with lower technical credentials won a new account because their content positioned them as the authority first
What They Need to Believe
That marketing content can carry the firm's technical credibility to accounts that haven't met the founder -- and that building a content system won't create an ongoing liability for inaccuracy that the technical team has to manage.
Their Personal Stakes
Justify the existence of a BD function in a company that grew without one. They need the CEO or founder to trust that a marketing system won't dilute the firm's technical brand -- which means they must sell the investment internally before any external system can be built. Their internal selling motion mirrors their clients' own: a champion trying to move a technically conservative decision-maker to act on something they can't yet see the output of.
How They Make Decisions
Will champion the investment but cannot commit without founder buy-in. The bottleneck is the founder, not the budget. The most powerful framing is a business case the technical founder finds credible -- accuracy controls, output governance, and proof that the system won't produce content requiring engineering review before publication. Pipeline metrics matter: "what will this do for our inbound inquiry rate?"
What They've Already Tried
Relying on the founder's speaking schedule and personal reputation to generate pipeline. Attending conferences without supporting content to extend that presence beyond the room. Starting LinkedIn posts that die without a strategy or system behind them. They know what the gap looks like -- they feel it every quarter when pipeline reviews reveal that every lead came from one person's rolodex.
- Computer Software Validation (CSV) and Computer System Validation (CSVal) consultancies
- Quality Management Systems (QMS) and document control software vendors
- Serialization and track-and-trace compliance technology firms
- LIMS, ELN, and MES software companies serving regulated industries
- Data integrity and audit trail consulting practices
- Regulatory submission software and eCTD tools
- General enterprise software or SaaS companies with no life sciences vertical
- General IT consulting or managed services without regulatory focus
- Healthcare IT serving hospitals or payers without pharma/biotech application
- Cybersecurity firms with no GxP or 21 CFR Part 11 expertise
- Company explicitly serves FDA-regulated industries: 21 CFR Part 11, Annex 11 mentioned on website
- Company size 10 to 300 employees
- Posting on LinkedIn 2x or more per month about regulatory or compliance topics
- Sponsors or speaks at ISPE, PDA, or DIA events
- Current marketing or demand generation job posting
- Recent product release tied to FDA guidance or EU GMP update
- Life sciences as one vertical among several
- Company size 5 to 10 or 300 to 1,000
- Compliance content is on the website but not being published regularly
- Some event presence but not leading with regulatory credibility
- No open marketing role; marketing owned by founders or product leads
- No visible regulated industry practice or certification
- Under 5 or over 1,000 employees
- General IT or SaaS with life sciences as a footnote
- No English-speaking North America or Europe contact
- Company is actively being acquired or merging
- Founder or CEO posting about compliance topics personally but company page is inactive
- Product or software update announcements with no follow-through content
- Job posting for: Marketing Manager, Demand Gen Specialist, Content Writer with regulatory experience preferred
- Low LinkedIn follower count relative to the number of pharmaceutical clients they claim
- Posts that explain a regulation but don't connect back to their product or service
- Conference appearances without pre-show or post-show content follow-up
- Website has regulatory expertise on the about page but no content program to demonstrate it
- Case studies are PDFs that haven't been updated in 2 or more years
- Listed as a vendor on pharma industry directories but no outbound presence
- Recent FDA warning letter, EU GMP update, or industry guidance that directly affects their solution with no timely response content from them
- News coverage of a compliance failure at a pharma client creates an opening for their category
- Be found by pharma buyers searching for compliance solutions before issuing an RFP
- Build thought leadership credibility that shortens the sales cycle
- Expand into new geographies or therapeutic area verticals
- Get more marketing output than the current founder-does-it-all model allows
- Establish a pipeline that doesn't depend entirely on referrals from existing clients
- Product is technically superior but pharma buyers don't know about it
- The founder understands the compliance landscape but can't write consistent content while running a company
- Marketing spend is going to general IT or tech channels that don't reach pharma QA or IT teams
- Competitors with worse products are winning deals because they're more visible
- Regulatory guidance changes require timely content responses they can never produce fast enough
- Regulatory accuracy: content must not misrepresent FDA or EU GMP requirements
- Credibility above all: in this market, one wrong technical statement damages trust permanently
- Marketing that reaches the actual buyer: QA managers, IT compliance leads, validation engineers
- Speed to market: regulatory changes create brief windows where timely content wins
- Ownership of their positioning: they built the expertise and want a partner, not a ghostwriter who takes over
- Publishing content that cites FDA guidance incorrectly and damages credibility with their most sophisticated buyers
- Being replaced by a larger competitor who buys visibility they can't match organically
- Investing in marketing that reaches the wrong audience: general IT buyers, not pharma compliance teams
- Losing a deal to a competitor who produced a white paper or webinar faster after a guidance update
- AI producing generic compliance content that makes them look like everyone else
| What They're Currently Using | Typical Weakness or Gap | Your Displacement Angle |
|---|---|---|
| Founder-led marketing CEO writes the blog posts and LinkedIn content personally |
Inconsistent cadence; drops off during project delivery; content tied to one person's bandwidth | Build a system that captures the founder's expertise and outputs it consistently, without requiring the founder to write anything. |
| General SaaS or tech marketing agency No regulated industry experience |
Produces generic content that doesn't reach pharma buyers and doesn't demonstrate regulatory depth | Life sciences and regulatory expertise from the first draft: no onboarding ramp, no fact-checking delay, no content that misses the buyer's vocabulary. |
| Internal junior marketer One content coordinator handling everything |
Can execute but cannot write with regulatory depth; constantly needs expert review | You sit above the coordinator: you provide the strategy, the expert-level content framework, and the AI infrastructure; they execute against it. |
| No marketing investment Word of mouth and conference attendance only |
Pipeline is entirely referral-dependent; invisible to buyers who aren't already in the network | Build the first scalable outbound presence: LinkedIn, content, and thought leadership that reaches buyers before the referral conversation happens. |
"There's a very specific kind of marketing problem that digital and compliance firms in pharma face: you have the deepest expertise in the room, but the buyers don't know you exist until someone they trust mentions you. I've spent nearly 20 years in biopharma marketing, and I know how to build the kind of presence that gets you found before the referral."
"Here is what I see consistently: excellent CSV consultants, outstanding QMS vendors, highly credentialed compliance firms, all relying on referrals and conference attendance while their competitors with lesser expertise are winning deals because they have white papers, LinkedIn content, and a visible point of view. That's not a product problem. That's a marketing infrastructure problem."
"What Good Bones Marketing builds is marketing infrastructure powered by AI that converts your regulatory expertise into a consistent thought leadership program. White papers drafted from your existing documentation. LinkedIn content built around the guidance updates you're already tracking. Lead magnets and outreach sequences calibrated to pharma QA and IT compliance buyers. All of it running consistently without requiring you to write a word."
"Hi [Name], I've spent nearly 20 years in biopharma marketing, and the most common pattern I see with compliance and digital infrastructure firms is: outstanding expertise, thin external presence. Your buyers are searching for CSV consultants, QMS vendors, and data integrity specialists before they issue an RFP. I help firms like yours build the marketing infrastructure that gets them found at that moment. Would it be worth 20 minutes to see if this is relevant for where you're trying to grow?"
Referrals are your strongest signal. But they are also your ceiling. Every referral you get is from someone who already knows you. The question is: how do you reach the buyers who don't know anyone who knows you yet?
You're right that off-the-shelf AI can't. What I build is different: the AI works from your existing documentation, training materials, and expert input. Your team reviews before publication. The accuracy is your responsibility; the AI just removes the writing bottleneck.
Tell me about that experience. In most cases, the agency didn't understand the buyer, didn't understand the regulation, or produced generic content that didn't reach the right audience. What I do is different at the foundation level, not just in execution.
| Channel | Key Events and Venues | Approach | Cadence |
|---|---|---|---|
| ISPE and PDA Events | ISPE Annual Meeting, PDA Annual Meeting, DIA Annual Meeting | Target the vendor and sponsor sections. Use Sandra's ISPE chapter role as a warm entry point. Look for firms sponsoring or speaking on CSV, data integrity, and digital topics. | 3 to 4 national events per year |
| Founders, technical directors, compliance leads at target firms | Find founders who post compliance insights but whose company pages are dormant. Comment on content first. Connect after 2 to 3 meaningful comments. DM as soon as connected. | Daily monitoring; timing outreach around regulatory guidance releases | |
| Email Outreach | Founders, CEOs, VPs of Sales or Marketing | Lead with the expertise gap insight. Reference a specific piece of guidance (FDA, EU GMP) that directly affects their solution. Under 150 words. Avoid SaaS marketing language. | 3-touch sequence over 3 weeks; quarterly nurture for Tier 2 |
| Regulatory Trigger Events | FDA guidance releases, EMA updates, 483 observation trends | When a major guidance is released that affects their category, reach out within 72 hours. Position the message as a timely opportunity to be the first voice on the topic. | As needed; target firms that don't respond publicly to guidance updates |
Pull the company on LinkedIn and their website. Answer each question. Total score determines tier assignment.
| # | Qualifying Question | Pts | Y? |
|---|---|---|---|
| 1 | Does the company explicitly serve FDA or EU GMP regulated environments (21 CFR Part 11, Annex 11, or GxP mentioned)? | 2 | |
| 2 | Is company size between 5 and 1,000 employees? | 1 | |
| 3 | Is there an accessible English-speaking contact in North America or Europe? | 1 | |
| 4 | Is there visible marketing investment or a clear gap between their expertise and their public presence? | 2 | |
| 5 | Does the company have fewer than 3 internal marketers, or is marketing owned by the founder or product team? | 1 | |
| 6 | Is there a recent regulatory trigger (new guidance, enforcement action) in their category that creates urgency for content? | 1 | |
| 7 | Is the company NOT a general IT firm and NOT a pharma or biotech end-user? | 1 | |
| 8 | Has there been a trigger event in the last 90 days: product launch, conference appearance, hire, or regulatory announcement? | 1 |
- General enterprise software or IT consulting with no pharma/biotech application
- Healthcare IT serving only hospitals, payers, or health systems (non-regulated manufacturing)
- Pharma or biotech manufacturers who are the end-users of these tools, not the providers
- Companies with no English-speaking contact in North America or Europe
- Firms that have already signed with a competing life sciences marketing agency
- Companies over 1,000 employees: likely have an established marketing function; longer sales cycle for external agency
- Firms where the founder is the sole decision-maker AND is extremely time-constrained: buying cycle will be slow even if interest is high
- Startups under 2 years old: often pre-revenue or pre-product-market-fit; marketing investment is premature
AI is restructuring agency pricing and delivery models faster than most principals anticipated. Agencies that productize AI workflows into a documented, client-facing capability command premium pricing and reduce competitive exposure to offshore content mills and AI-native competitors entering from adjacent markets.
Marketing Agencies
Who They Are
Small to mid-size marketing, digital, creative, and PR agencies whose owners built their practice on craft — and are now under pressure to integrate AI before clients start asking why they haven't. Often 1–25 employees. The buyer is the founder or managing partner, making the call independently. They've likely tried off-the-shelf AI tools and found the results generic. What they need is a real system, not a shortcut.
What Makes Them Ready to Engage
- A client asked "are you using AI?" and they didn't have a confident answer
- A competitor agency won a pitch by leading with AI capabilities
- Production costs are rising and they need leverage without adding headcount
- They tried to build AI workflows themselves and it took more time than it saved
- They want to offer AI-powered services to clients but don't know where to start
What They Need to Believe
That the system will make their work better without making it feel generic — and that the implementation won't require them to rebuild how they work from scratch.
Where to Reach Them
Psychographic Profile (OCEAN)
- Medical communications and medical affairs agencies already serving pharma
- Healthcare marketing agencies building or expanding life sciences practices
- PR firms with regulated industry portfolios wanting to add digital or content capabilities
- Scientific communications firms transitioning from publication support to broader BD support
- Small AEC or industry specialty marketing agencies adding a life sciences vertical
- General digital or creative agencies with no regulated industry experience or interest
- Large full-service agencies with mature life sciences practices and their own AI infrastructure
- Agencies whose primary revenue is from pharma advertising (DTC) rather than B2B marketing
- Social media agencies with no B2B or technical content capability
- Agency actively pitching or serving life sciences B2B clients
- Agency size 5 to 100 employees
- Leadership has a scientific or regulatory background visible on LinkedIn
- Currently posting about pharma, biotech, or AEC marketing topics
- Open role for life sciences content writer, account manager, or strategist
- Recent client win in life sciences or case study published in the sector
- Agency serves healthcare broadly but not specifically regulated manufacturing
- Size 3 to 5 or 100 to 500
- Interested in life sciences but hasn't made a formal practice investment
- Agency leadership has a general marketing background, not scientific
- No current life sciences-specific open roles
- General-purpose agency with no regulated industry work or interest
- Agency focused on DTC pharma advertising, not B2B life sciences marketing
- Large holding company or network agency with established life sciences division
- Social-media-only or influencer-focused agencies
- Agency leadership posting about life sciences B2B marketing opportunities
- Job postings for scientific content writers, medical writers, or life sciences strategists
- Agency announcing a new pharmaceutical, biotech, or AEC client win
- Agency sharing content about AI in marketing with no clear life sciences application yet
- Agency leadership commenting on ISPE, PDA, or biopharma industry posts
- Agency website update adding a life sciences or healthcare page
- Agency website has a "Healthcare" vertical but no regulatory or GMP-specific capability mentioned
- Case studies show adjacent sectors (medical devices, diagnostics) but not pharma manufacturing or AEC
- Agency principals have scientific or pharma career backgrounds based on LinkedIn bios
- Agency recently presenting at a healthcare marketing conference on B2B or content strategy
- Agency's existing clients include life sciences industry associations, AEC firms, or pharma suppliers
- Add a profitable life sciences vertical without hiring expensive scientific staff
- Use AI-powered infrastructure to scale delivery without proportionally scaling headcount
- Win and retain clients who are harder for generalist agencies to serve
- Establish credibility in regulated industries to command higher retainer rates
- Become the go-to partner for B2B life sciences clients in their market
- Cannot write accurately for life sciences without a scientific expert on staff
- Losing life sciences pitches to specialist agencies with industry credibility
- Delivery margin is thin: every client requires heavy customization without a repeatable system
- AI tools they've tried don't produce life sciences content that passes client review
- Life sciences clients require faster turnaround and higher accuracy than their general process can deliver
- Delivery quality: they cannot put their agency brand on work that fails a pharma client's review
- Speed and repeatability: they want systems that scale, not one-off expert hours
- White-label or partnership model: they want to bring the capability in-house, not refer clients away
- Proven track record: they won't pilot with an untested process on a valued client
- Economic alignment: the partnership has to protect their margin, not erode it
- Producing content that fails client review and damages the agency's reputation with a strategic account
- Over-investing in a life sciences capability that doesn't close enough new business to justify it
- Becoming dependent on a subcontractor who can go direct to their clients
- Being exposed as not truly expert in life sciences during a competitive pitch
- AI producing generic content that life sciences clients immediately recognize as low-quality
| What They're Currently Using | Typical Weakness or Gap | Your Displacement Angle |
|---|---|---|
| General medical writers or freelancers Hired project by project |
Inconsistent, expensive per project, no systematic approach, no AI integration | A replicable life sciences content infrastructure they can deploy across clients, not a freelancer they re-brief every engagement. |
| General AI tools ChatGPT or generic AI for content generation |
Produces content that fails life sciences client review because it lacks regulatory accuracy and industry specificity | Life sciences-trained AI infrastructure built on GBM's frameworks: content that passes pharma and AEC client review without a full rewrite. |
| In-house capability building Hiring a life sciences content specialist |
Expensive, slow to hire, single point of failure, limited scope | Faster to activate, broader in scope, and doesn't add headcount to a margin-sensitive model. |
| Referring life sciences work to specialist agencies Passing the opportunity away |
Lost revenue, lost client relationship, no learning or brand building in the sector | Keep the client and the revenue by bringing GBM's capability in as a white-label foundation. |
"Life sciences B2B is one of the most consistently underserved markets for agency work. The clients are well-funded, the retainers are meaningful, and the competition from specialist agencies is beatable, if you have the right infrastructure. I've spent nearly 20 years in biopharma marketing building exactly that infrastructure, and I work with agencies who want to serve this market without hiring a team of scientific writers."
"Here's what I see with agencies in your position: you know the life sciences market is valuable, you may have picked up a client or two, but the delivery infrastructure isn't there to make it repeatable or scalable. Every project is custom, every content piece requires an expert review loop, and the margin gets eaten by the rework. That's not a skill gap. That's a systems gap."
"What I offer agencies is a partnership model: GBM's life sciences marketing infrastructure, AI-powered and built for regulated industries, made available to you as a white-label foundation for your client work. You get the capability without the headcount. Your clients get better output. You keep the relationship and the margin."
"Hi [Name], life sciences B2B is one of the best-funded and most underserved markets for agency work. The reason most agencies don't capture it isn't strategy: it's infrastructure. Writing for pharma buyers requires regulatory fluency that generic processes can't produce. I've spent nearly 20 years in biopharma marketing, and I work with agencies who want to build or expand their life sciences practice without adding scientific headcount. Would it make sense to have a 20-minute conversation about what that could look like for your team?"
That's a legitimate concern, and it's addressed directly in how the partnership is structured: I sign your NDA and work under your agency's brand. Your clients don't need to know the infrastructure behind the work, and I have no interest in going direct.
Most agencies do. The question is whether those tools are producing output that passes life sciences client review without significant rework. If the answer is yes, you don't need me. If there's still a gap, what I offer is infrastructure purpose-built for this specific market.
That's a valid path, and it can be the right one long-term. But it takes 12 to 18 months to hire the right person, train them, and build the process. What does your life sciences pipeline look like while that's happening? Partnering now doesn't preclude building later.
| Channel | Key Events and Venues | Approach | Cadence |
|---|---|---|---|
| Healthcare Marketing Conferences | Healthcare Marketing and Physician Strategies Summit, Digital Pharma East, PM360 Think Tank | Target agency principals on attendee lists. Position GBM as an infrastructure and AI partner, not a competitor. Warm conversation first. | 2 to 3 per year |
| Agency founders, VPs of Strategy, Client Services Directors | Find agencies posting about expanding into life sciences or struggling with pharma content. Comment thoughtfully before reaching out. Lead with partnership value, not GBM's own brand. | Daily monitoring; react within 24 hours of a relevant post | |
| Direct Email | Agency owners and founders at target firms | Lead with the life sciences revenue opportunity, not GBM's services. Frame as a capability conversation. Reference something specific about their agency's current work or positioning. | 3-touch sequence; follow up in 3 and 7 days if no response |
| SMPS and AMA | SMPS Annual Conference, AMA chapters serving B2B marketers | Attend sessions on healthcare and tech marketing. Introduce GBM as a resource for agencies wanting to serve life sciences clients. Speaking opportunity if available. | 1 to 2 per year |
Pull the agency on LinkedIn and their website. Answer each question. Total score determines tier assignment.
| # | Qualifying Question | Pts | Y? |
|---|---|---|---|
| 1 | Does the agency serve B2B clients in healthcare, pharma, biotech, AEC, or adjacent life sciences sectors? | 2 | |
| 2 | Is agency size between 3 and 100 employees? | 1 | |
| 3 | Is there an accessible decision-maker (owner, founder, or VP) I can reach directly? | 1 | |
| 4 | Does the agency lack a dedicated life sciences content infrastructure or is relying on generalist processes for regulated industry clients? | 2 | |
| 5 | Is the agency actively trying to win or expand life sciences clients (signal on LinkedIn, case studies, or job postings)? | 1 | |
| 6 | Is there a partnership or white-label model that would work economically for both parties? | 1 | |
| 7 | Is the agency NOT a large network or holding company agency with its own established life sciences division? | 1 | |
| 8 | Has there been a trigger event in the last 90 days: new life sciences client announced, job posting, relevant conference appearance? | 1 |
- Large holding company or network agencies with an established life sciences marketing division
- Agencies focused exclusively on DTC pharma advertising (not B2B life sciences)
- Social-media-only or influencer-focused agencies with no B2B content capability
- Agencies with no interest in regulated industries: general retail, CPG, entertainment
- Agencies that are direct competitors marketing themselves as life sciences specialists
- Agencies over 100 employees: may have internal specialization already; slower buying decision
- Agencies primarily serving medical devices or diagnostics with no pharma manufacturing or AEC client experience: adjacent but may need more education on the GBM framework
- Agencies in early-stage client acquisition mode (under 2 years old) where client concentration risk makes them hesitant to commit to a subcontractor relationship
The barrier between small business owners and scalable content production is collapsing as AI infrastructure becomes accessible below the enterprise tier. Owners who build a systematized marketing approach early gain a compounding visibility advantage over competitors relying on ad hoc posting, and the cost of delay is increasingly visible in referral-dependent businesses whose networks are saturating.
Small Businesses and Entrepreneurs
Who They Are
Founders, solopreneurs, independent consultants, and small business owners who are doing marketing themselves or with a very small team. Excellent at their core work. Marketing takes a back seat. The buyer IS the decision-maker — there's no approval chain. They've likely tried ad hoc tools or sporadic social posting and found it inconsistent and exhausting. They don't need more content advice. They need a system that runs without them having to think about it every week.
What Makes Them Ready to Engage
- Referrals dried up and they realized visibility was entirely relationship-dependent
- Tried a marketing agency and found it too expensive for their stage — or too generic
- Peer business owner described what an AI system is doing for their marketing
- Spending hours per week on content with inconsistent results
- Want to grow but can't afford to hire a marketing person yet
What They Need to Believe
That the system will largely run without them once it's set up — and that it will sound like them, not like a robot. The single biggest fear is paying for something that produces content they're embarrassed to post.
Where to Reach Them
Psychographic Profile (OCEAN)
- Independent regulatory affairs consultants and boutique RA firms
- Solo or small CQV and validation specialists building a practice
- Fractional quality and compliance professionals going independent
- Small technical training providers serving pharma and biotech
- Independent scientific writers and content strategists specializing in life sciences
- Boutique life sciences executive recruiters and HR consultants
- Freelancers with no intention of scaling beyond solo practice
- Independent practitioners outside life sciences with no path to the GBM core audience
- Entrepreneurs in pre-revenue or idea-stage with no active client pipeline
- Side-business owners where life sciences work is not the primary revenue stream
- Life sciences specialty is clear: RA, CQV, quality, training, or scientific communications
- Revenue-generating: at least 1 to 2 active clients or projects in the last 6 months
- Posting on LinkedIn or has a website but with no consistent strategy
- Recently left pharma or biotech to go independent (high motivation)
- Expressed frustration with getting found or winning clients on LinkedIn
- Budget: $5K to $15K service range aligned with GBM entry offerings
- Life sciences background but still employed full-time (considering going independent)
- 1 to 2 years into independence but not yet at sustainable revenue
- Interested in marketing but budget signals are unclear
- Social media presence is aspirational but not yet consistent
- Pre-revenue or still considering whether to go independent
- No life sciences background or unclear specialty
- No budget ceiling that aligns with GBM's minimum engagement
- Primarily looking for free advice or tools rather than a paid engagement
- Posting expert life sciences content but with low engagement and no strategy behind the frequency or topics
- "Open to work" or recent announcement of going independent from a pharma or biotech company
- Commenting on LinkedIn posts about personal branding, consulting, or small business marketing
- Profile says "independent consultant" or "founder" but has no compelling about section or service description
- Posting about a recent client win or project but not consistently following up with related content
- Asking questions in life sciences LinkedIn groups about how to get more visibility or clients
- Website is a basic template or doesn't exist: no case studies, no services page, no value proposition
- Active on industry forums or professional associations (ISPE, RAPS, ASQ) but no standalone brand presence
- Google search for their name returns no professional content beyond LinkedIn
- LinkedIn recommendations and endorsements show depth of expertise but they're not publishing content about it
- RAPS or ISPE member directory listing with no other online presence
- Build a sustainable pipeline of clients without full dependence on referrals
- Become recognized as a go-to expert in their specialty on LinkedIn and in their professional community
- Move from reactive (waiting for someone to reach out) to proactive (being found and chosen)
- Charge premium rates because their expertise is visible and differentiated
- Build a business, not just a job: systems that generate leads even when they're heads-down with clients
- Revenue is inconsistent because pipeline depends entirely on referrals and word of mouth
- They're excellent at their craft but nobody outside their existing network knows it
- LinkedIn feels like a full-time job: they don't know what to post or how often
- They know they should be marketing but every tool or agency feels designed for a bigger company
- Every proposal they write for a new client is from scratch with no repeatable infrastructure
- Authenticity: they've built a reputation in a small industry and won't risk it on content that doesn't sound like them
- Practical ROI: they are spending real money from personal revenue; it has to lead to client conversations
- Speed to results: they can't wait 6 months to see whether a marketing program is working
- A partner who understands their specialty: can't explain what a 483 observation is to their marketing partner
- Control: they want to own their tools and systems, not rent access that disappears when the engagement ends
- Spending $5K to $10K on marketing and ending up with content that doesn't sound like them or reach their buyers
- Looking like they're trying too hard or being "salesy" in an industry where reputation is everything
- AI producing generic content that makes them indistinguishable from every other consultant
- Being dependent on a marketing partner they can't afford to keep long-term
- Running out of runway if client acquisition stays unpredictable through year 2 and 3
| What They're Currently Using | Typical Weakness or Gap | Your Displacement Angle |
|---|---|---|
| Doing it themselves Sporadic LinkedIn posts, no strategy |
Inconsistent, time-consuming, content quality varies, no clear positioning emerging | A built infrastructure that runs consistently with minimal time from the consultant: content, voice, positioning, all established in week one. |
| General LinkedIn coaches or personal brand consultants No life sciences expertise |
Can teach posting strategy but can't write in the language of a GMP environment or a pharma buyer | Coaching plus execution, in the language of their industry, delivered by someone who has worked with their clients. |
| DIY with AI tools Trying ChatGPT or Jasper for content |
Generic output that doesn't capture their expert voice or regulatory precision | AI infrastructure built on their specific expertise and voice: the output sounds like them because it's built from what they know. |
| Nothing: waiting for referrals No active marketing investment |
Pipeline is invisible, inconsistent, and entirely dependent on the goodwill of existing clients | The first systematic marketing infrastructure they've ever had: designed for a one-person or small business, not a corporate team. |
"There's a specific pattern I see with independent life sciences consultants: deep expertise, invisible brand. You know your specialty inside and out. Your past clients would recommend you without hesitation. But when a pharma quality director or biotech founder is searching for exactly what you do, you don't come up. I've spent nearly 20 years in biopharma marketing, and I help consultants like you solve that problem."
"Here's what I hear most often from independent consultants in your position: they know they should be on LinkedIn, they know they should be posting, they know they should have a clearer service offering on their website, but every day it gets pushed behind client work. That's not a motivation problem. That's a systems problem. When you have to write every post from scratch, review your own positioning, and figure out what to say next, it never gets done."
"I offer a Growth Audit as a starting point: a 90-minute session where we map your expertise, your ideal client, your current positioning, and what's keeping you invisible. You leave with a clear picture of what needs to change and a plan to change it. Whether or not we work together after that is entirely your call. Most people find it's the most useful marketing conversation they've had since going independent."
"Hi [Name], I noticed your background in [regulatory affairs / CQV / quality systems]: the kind of expertise that's genuinely hard to find in the market. I work with independent life sciences consultants who are excellent at what they do but haven't built the marketing infrastructure to be consistently found and chosen by new clients. I'd love to offer you a complimentary 30-minute call to see whether that's a challenge you're facing and whether the Growth Audit I offer might help. No obligation, just a conversation."
I understand: that's usually the reality when pipeline is thin. But here's the challenge: the revenue problem is the marketing problem. The Growth Audit is designed to give you a clear, actionable plan that doesn't require a large investment to start implementing. Let's start there before we talk about anything bigger.
Most independent consultants in life sciences feel this way. What changes the equation is publishing content in the language of your buyers, in the places they're looking, at the moments when they're searching. The people who have built a presence in regulatory affairs and CQV have done exactly that. It works: the question is having the right system to do it consistently.
That discomfort is common and it's actually a signal that you're doing it wrong. The most effective positioning for consultants isn't self-promotion: it's education. When you're teaching pharma buyers what they need to know about validation strategy or RA submissions, you're demonstrating expertise, not advertising yourself. That's what we build.
| Channel | Key Events and Venues | Approach | Cadence |
|---|---|---|---|
| Life sciences consultant profiles, ISPE and RAPS group discussions | Find consultants posting inconsistently about their specialty. Comment on their expert posts before connecting. Frame the conversation around helping them be found, not about selling marketing services. | Daily monitoring; reach out within 24 hours of a relevant post or transition announcement | |
| Professional Associations | RAPS Annual Meeting, ISPE chapter events, ASQ Biomedical Division, PDA Training | Attend events where independent consultants network. Position GBM as a resource. The Growth Audit is the right entry point for this segment: low risk, high value. | 3 to 5 relevant events per year |
| Direct LinkedIn DM | Immediate post-transition outreach: when someone announces they're going independent | Send a congratulations message within 48 hours of an "I'm now independent" announcement. Introduce GBM as a resource for building their practice. Offer the free 30-minute call, not a pitch. | React within 48 hours of every target's transition announcement |
| Content Marketing | GBM's own LinkedIn page and Sandra's personal profile | Publish content directly addressing independent consultant challenges: how to get found, how to price, how to write on LinkedIn without feeling like you're selling yourself. Inbound works for this segment. | 2 to 3 posts per week; at least 1 specifically addressing the independent consultant audience |
Pull the person's LinkedIn profile. Answer each question. Total score determines outreach priority.
| # | Qualifying Question | Pts | Y? |
|---|---|---|---|
| 1 | Does the person have a clear life sciences specialty: RA, CQV, quality systems, scientific communications, or similar? | 2 | |
| 2 | Are they actively operating independently (not full-time employed) with at least 1 active or recent client? | 2 | |
| 3 | Is there a visible gap between their expertise and their online presence (great credentials, thin content)? | 2 | |
| 4 | Are they based in North America or Europe with English-language professional materials? | 1 | |
| 5 | Is there a budget signal: charging $150 or more per hour or a service offering with documented rates? | 1 | |
| 6 | Is there a recent trigger: new independence announcement, LinkedIn post asking about marketing, or industry event attendance? | 1 | |
| 7 | Are they NOT pre-revenue, NOT a full-time employee, and NOT looking for free advice only? | 1 |
- Full-time employees at pharma, biotech, or AEC companies: not independent, not a buyer for GBM services
- Pre-revenue entrepreneurs with no active client pipeline and no clarity on service offering
- Consultants outside life sciences with no path to the GBM core buyer audience
- People looking for free advice, tools, or templates rather than a paid engagement
- Individuals with no presence in English-language professional channels in North America or Europe
- Consultants in the first 6 months of independence: may not yet have budget certainty for a marketing investment
- Individuals who are primarily freelancers with no intention of scaling to a firm or building a pipeline beyond referrals
- Consultants in geographies outside North America and Europe: engagement is harder to sustain without shared time zones and English-primary communication
Your Competitive Position
Where you sit in the market, what sets you apart from every alternative your buyers have tried, and what you deliberately don't do. This is the positioning layer of your infrastructure.
Where You Sit in the Market
This map shows your position relative to the alternatives your buyers have already tried. The two axes that matter most for life sciences AEC and supplier buyers are industry depth and AI capability — because those are the two things generic agencies and generic tools consistently fail to deliver together.
Marketing
Tools
Agencies
Specialists
High specialist · High AI
High AI · Low specialist
Low AI · Low specialist
High specialist · No AI
What Sets You Apart
The reason a VP of BD at an EPCM firm will trust your analysis of their buyer, your understanding of their proposal process, and your judgment about what will and won't land in a GMP-facility client's inbox. When you describe a buyer's situation, you are describing what you have watched happen in ISPE committee rooms, on proposal review calls, and in the feedback loops of fifteen-plus Facility of the Year submissions.
The marketing and BD infrastructure built by Good Bones Marketing is trained on the client's own materials — their actual project descriptions, proposal language, case study vocabulary, brand voice. When the engagement ends, the infrastructure stays. The knowledge stays. No institutional knowledge walking out the door.
In a market where buyers evaluate partners through community membership and industry standing, these facts carry more weight than any case study. They signal permanent community membership — not a vendor who discovered life sciences marketing and is now positioning around it.
Most marketing firms are trying to add AI capabilities to existing service lines. Good Bones Marketing built the compliance governance layer first — because the regulated-environment buyer's primary objection to AI is known before any conversation even starts.
Buyers in your market do not make quick commitments to marketing partners. Offering a structured, free diagnostic that produces a specific, usable growth plan — before any engagement is proposed — removes commitment friction at exactly the right moment in the buying journey.
What You Replace
What You Don't Do — and Why That's a Strength
Good Bones Marketing does not serve pharmaceutical manufacturers, CDMOs, biotech companies, cell and gene therapy firms, hospitals, health systems, or medical device manufacturers. This boundary is not a limitation — it is the clearest possible signal of a specialist. The firms you serve are selling to these organizations. That means you are never in a position of divided loyalty. The clearest sign of expertise is what a firm says no to.
How the five competitive forces shape your position in the life sciences AEC marketing space. Click any force to see the full analysis and strategic implication.
A visual alignment of Good Bones Marketing's core revenue generators. Click any service bubble to see the full analysis. The matrix positions each service by market growth rate (vertical axis) and your current competitive position (horizontal axis).
Your Voice
The brand archetypes that define your role, the voice dimensions your communications sit on, and the writing rules applied across every output. This is the voice layer of your infrastructure — the rules that make your communications consistent regardless of who uses them.
Analysis Source
The voice analysis reviewed your complete intake responses, your published website (goodbonesmarketing.com — homepage, services, about, process, testimonial), and your marketing flyer (GBM-Flyer3.pdf). No LinkedIn posts or email samples were available. One notable finding: your intake described your voice as conversational, but your website reads as semi-formal. Your flyer is consistent with your intake description. We weighted the flyer and intake over the website copy — the website should be updated to align with your actual voice once the system is active.
Your Brand Archetypes
The trusted expert whose authority comes from depth of knowledge, not volume of presence. Calm, specific, credible. The communication that makes a VP of BD think "this person understands exactly what I'm dealing with."
Adds the dimension of building things rather than just advising. Systems, frameworks, and infrastructure that remain with the client. The practice is a workshop, not just a consultancy.
The orientation toward transformation — the before and the after, with the infrastructure as the mechanism. What changes isn't just the output. It's the underlying marketing capability.
Voice Spectrum
Where your brand communications sit on each dimension, based on analysis across all available materials. These calibrate how every piece of output should be written.
The Rules We Write By
These rules are applied to every output from your infrastructure. Edit any rule that doesn't match how you actually communicate, or add rules that are missing.
- We open with the point. Your audience is too experienced to sit through a build-up.
- We name specific problems. "Your marketing program lives in one person's head" is better than "marketing systems that lack resilience."
- We use your vocabulary correctly and without performing it. GMP, EPCM, CQV, ISPE, SMPS appear naturally when the audience expects them.
- We write as you, not as a firm. First person singular, because you are the practice.
- We end with something worth ending on — an observation, an invitation, the point itself. Not a summary.
- We never produce output that reads like AI generated it. If it sounds templated, it gets rewritten before it reaches you.
- We do not overstate. Your buyers will check claims. Every assertion has a basis.
How You'll Go to Market
Your infrastructure defines who you are. This section defines how you activate it. Channels, BD touchpoints, and a content strategy are all applications of the infrastructure you've just confirmed — not the infrastructure itself.
Primary Channel: LinkedIn
LinkedIn is where all three of your buyer segments actively evaluate vendors and partners. It is the channel where your industry credentials, community membership, and voice can work together. The strategy below is one application of your Backbone infrastructure — the same infrastructure can power proposals, capability statements, website copy, BD outreach, and any other output your team needs.
Recommended Content Mix
Platform: LinkedIn personal profile + company page
Cadence: Tuesdays & Thursdays + reactive
First Application: LinkedIn Content (8 Posts)
Your first content batch is one output from your infrastructure. Produced after you activate the system — you'll approve every piece before anything is published.
This is one application. The same infrastructure also powers your proposals, website, BD outreach, and any content your team needs to stay consistent.
Content Pillars
These five pillars structure the LinkedIn strategy. Each can be expanded with post ideas below. In edit mode, adjust counts or add ideas.
Builds authority and gives buyers a reason to follow. Demonstrates domain knowledge in specific, readable form.
- What the ISPE Facility of the Year Award actually measures — and what it says about a firm's marketing capability
- The one-person marketing department problem: why life sciences AEC firms keep rebuilding from scratch
- Why GMP-ready AI content is different from regular AI content (and how your buyers will know the difference)
- The proposal shortlist problem: what EPCM firms with strong credentials get wrong
Positions you as the named voice on AI governance in regulated environments and life sciences marketing strategy.
- The AI governance gap in life sciences marketing — and why generic tools create credibility risk for regulated-environment firms
- Twenty years of ISPE: what's changed about how regulated-environment buyers evaluate suppliers — and what hasn't
Converts warm leads. Each case study requires your explicit approval before use — no client is referenced without confirmation.
- How ERA Science went from scattered marketing to a consistent, recognizable presence in the life sciences AEC community
Growth Audit CTA or service reference. One promotional post per ten maintains credibility while creating a conversion opportunity.
- Growth Audit: a 90-minute session that maps exactly where your marketing program is losing pipeline — and what to do about it
Reactive — flagged as ISPE news, regulatory guidance, or industry events create the right moment. Positions you as someone actively watching what matters.
- New FDA AI guidance and what it actually means for marketing in GxP environments — a plain-language interpretation
- ISPE Annual Conference 2026: what life sciences AEC buyers are actually talking about this year
Event-Driven Activation Windows
| Event | Timing | Activation Angle |
|---|---|---|
| ISPE Annual Conference | June | Perspective on key themes; life sciences marketing lessons from the event |
| ISPE Facility of the Year Awards | Q3 – Q4 | Thought leadership on what award-winning projects teach about life sciences facility marketing |
| SMPS Annual Conference | July | BD and marketing best practices for AEC firms in technical markets |
| ISPE Delaware Valley Chapter Events | Quarterly | Local chapter content; founder's chapter president role creates native community visibility |
| FDA / EMA AI Guidance Releases | As published | Compliance-ready AI framing positioned around the new guidance |
Before We Activate
Seven items that need your confirmation before we finalize your infrastructure files and activate the system. Respond to each in the notes field below.
Your infrastructure covers all five segments you listed in your intake: (1) AEC and Facility Delivery firms as your primary segment, (2) Systems, Equipment, and Materials suppliers, (3) Digital, Quality, and Compliance infrastructure firms, (4) Marketing Agencies, and (5) Small Businesses and Entrepreneurs. Does this priority order match where you want your infrastructure focused in the next 12 months? And are there any segments where you want more or less content emphasis?
Your AI Automation Systems service serves all five segments, while Fractional Marketing Leadership is primarily positioned toward the life sciences segments. Confirm whether that split is accurate — and let us know if the content strategy should lean heavily toward one or two segments initially, or distribute evenly across all five.
- ERA Science / Andy O'Connor testimonial — currently the only confirmed, cleared reference. Please reconfirm it remains approved for use in infrastructure and output.
- "15+ ISPE Facility of the Year Award entries submitted on behalf of clients including WuXi Biologics, Janssen, Merck, and United Therapeutics" — before this language appears in any public-facing output, please confirm that referencing these firm names is appropriate. If any named firm would object, we need to use anonymized language.
- SMPS and Zweig marketing award winner — please confirm the specific award name(s) and year(s) for accurate use across all outputs.
Your intake listed "Brooke - Wright Mode" as a voice you want to sound like. Please confirm who or what this is so we can use their published work as a calibration sample in your brand voice file.
We plan to use LinkedIn native scheduling unless you tell us otherwise. If you have a preferred tool (Buffer, Hootsuite, or another), let us know before the first output batch is delivered.
The initial go-to-market strategy does not include an email newsletter. If you want to add one, confirm the platform you use or want to use and we will build that into the infrastructure.
Are there any companies or individuals that should never appear in your outputs or be targeted in outreach? If so, provide the list. If none, confirm so we can note this formally in your guardrails file.
Your Deliverables — What You're Receiving
These six files are your Backbone infrastructure. They are structured, usable, and portable — any team member, agency, or AI tool you work with can use them to stay consistent with your strategy.
Full buyer profiles for each segment — firmographics, OCEAN scores, buying triggers, journey stages, and what they need to see to say yes.
Your competitive position, five core differentiators, what you replace, and your boundary — the strategic layer behind every claim you make.
Archetypes, voice spectrum calibration, writing rules, and examples — everything needed to produce consistent, on-brand communications.
What you don't do, don't say, and don't represent — the explicit boundaries that protect brand credibility and keep all outputs on-strategy.
How the practice actually works — services, pricing model, delivery process, team structure, and engagement parameters. Context that makes outputs accurate.
Approved language, proven phrases, calibration examples, and on-brand references — the living library of what works.
Source Validation
This infrastructure was built entirely from your intake responses and your own published website and marketing materials. No third-party external sources were used.
| Source | Used For | Status |
|---|---|---|
| goodbonesmarketing.com | ICP audience profiles, brand voice analysis, positioning and differentiation language | Verified — client-owned |
| GBM-Flyer3.pdf | Sub-service descriptions, differentiators, founder credentials, ERA Science testimonial | Verified — client-owned |
Next Steps
Once you confirm this report is accurate, here is what happens:
- Your infrastructure activates. We apply any corrections you noted, finalize all six context files, and your Backbone Framework is live.
- First application. We generate your first LinkedIn content batch — 8 posts built directly from your infrastructure, delivered for your review before anything is published.
- Ongoing use. Your context files are yours to use for proposals, website copy, agency briefings, new hire onboarding, and any other marketing or BD output your organization needs.
If anything here doesn't match how you see your business, that is the right reaction. Use the notes fields above and submit your corrections below.
Submit Your Review
Once all five sections are approved, submitting sends your confirmations and notes to Good Bones Marketing.